Atossa Genetics Revenue and Competitors

Seattle, WA USA

Location

$32.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Atossa Genetics's estimated annual revenue is currently $1.7M per year.(i)
  • Atossa Genetics's estimated revenue per employee is $62,963
  • Atossa Genetics's total funding is $32.6M.

Employee Data

  • Atossa Genetics has 27 Employees.(i)
  • Atossa Genetics grew their employee count by 4% last year.

Atossa Genetics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$3.3M4310%$101MN/A
#4
$5.7M3712%N/AN/A
#5
$7M4541%N/AN/A
#6
$1.7M22-8%N/AN/A
#7
$3.9M504%$10.1MN/A
#8
$1.9M12-73%N/AN/A
#9
$29.3M151-17%$148MN/A
#10
$2M1386%N/AN/A
Add Company

What Is Atossa Genetics?

We are a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer.

keywords:N/A

$32.6M

Total Funding

27

Number of Employees

$1.7M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Atossa Genetics News

2013-05-15 - Angelina’s alternative: New test spots breast cancer risk at cellular level

A doctor collects fluid from each breast and sends the samples to Atossa’s CLIA-certified lab in Seattle, Washington. The National Reference Laboratory for Breast Health uses a proprietary analysis to study the fluid for precancerous cells. The results include treatment recommendations and prov ...

2011-06-27 - Atossa Genetics Completes $6.6M Financing Round

Atossa Genetics, Inc., a Seattle, WA-based health care company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer, has completed a $6.6m financing round. Investors remained undisclosed. The company intends to use the f ...

2011-06-27 - Atossa raises $6.6M to roll out a ‘Pap test for breast cancer’

Atossa Genetics, which is developing testing technologies to detect the presence of breast cancer, has raised $6.6 million in new financing in an oversubscribed round. The Seattle company plans to use the funds to bring its MACST System to market, establish a new molecular diagnostics lab in the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.4M27N/AN/A
#2
$2.7M27N/AN/A
#3
$3.6M270%$27.3M
#4
$4M270%N/A
#5
$4.2M27-23%N/A